Immunotherapy for melanoma: The good, the bad, and the future

Current Oncology Reports

Volumn 7, Issue 5, 2005, Pages 383-392

  Poehlein, Christian H ^b   Rüttinger, Dominik ^b   Ma, Jun ^b   Hu, Hong Ming ^b   Urba, Walter J ^b   Fox, Bernard A ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY; ANTINEOPLASTIC AGENT; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; OLIGONUCLEOTIDE; PEPTIDE DERIVATIVE; PERFORIN; PROSTAGLANDIN INHIBITOR; TOLL LIKE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN INHIBITOR;

ADOPTIVE TRANSFER; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL TRIAL; COLITIS; CPG ISLAND; CYTOKINE RELEASE; DRUG ERUPTION; HUMAN; HYPOPHYSITIS; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DEPLETION; MELANOMA; MOLECULAR DYNAMICS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR IMMUNITY;

EID: 24944562877     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0066-1     Document Type: Review

References (68)

1. Speiser DE, Lienard D, Rufer N, et al.: Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005, 115:739-746.
2. Ray CM, Kluk, Grin CM, Grant-Kels JM: Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol 2005, 44:428-434.
3. Watts TH: Tnf/Tnfr family members in costimulation of T cell responses. Annu Rev Immunol 2005, 23:23-68.
4. Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev Immunol 2005, 23:515-548.
5. Melero I, Shuford WW, Newby SA, et al.: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997, 3:682-685.
6. May KF Jr, Chen L, Zheng P, Liu Y: Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res 2002, 62:3459-3465.
7. Strome SE, Martin B, Flies D, et al.: Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma. J Immunother 2000, 23:430-437.
8. Weinberg AD, Rivera MM, Prell R, et al.: Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 2000, 164:2160-2169.
9. Kjaergaard J, Tanaka J, Kim JA, et al.: Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 2000, 60:5514-5521.
10. Kjaergaard JL, Peng PA, Cohen JA, et al.: Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol 2001, 167:6669-6677.
11. Leach D, Krummel M, Allison JE: Enhancement of antitumor immunity by CTLA-4 blockade [see comments]. Science 1996, 271:1734-1736.
12. Kwon ED, Hurwitz AA, Foster BA, et al.: Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997, 94:8099-8103.
13. Hurwitz AA, Yu TF, Leach DR, Allison JP: CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 1998, 95:10067-10071.
14. Phan GQ, Yang JC, Sherry RM, et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003, 100:8372-8377.
15. Hodi FS, Mihm MC, Soiffer RJ, et al.: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003, 100:4712-4717.
16. Robinson MR, Chan CC, Yang JC, et al.: Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 2004, 27:478-9.
17. Riley JL, June Ch: The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005, 105:13-21.
18. Mosmann TP, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more [see comments]. Immunol Today 1996, 17:138-146.
19. Aruga A, Aruga E, Tanigawa K, et al.: Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol 1997, 159:664-673.
20. Hu HM, Urba WJ, Fox BA: Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol 1998, 161:3033-3041.
21. Dobrzanski MJ, Reome JB, Dutton RW: Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin Immunol 2001, 98:70-84.
22. Winter H, Hu HM, Poehlein CH, et al.: Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies. Immunology 2003, 108:409-419.
23. Poehlein CH, Hu HM, Yamada J, et al.: TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J Immunol 2003, 170:2004-2013.
24. Lowes MA, Bishop GA, Crotty K, et al.: T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol 1997, 108:914-919.
25. Chu Y, Hu HM, Winter H, et al.: Examining the immune response in sentinel lymph nodes of mice and men. Eur J Nucl Med 1999, 26:S50-S53.
26. Meijer SL, Dols A, Urba WJ, et al.: Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J Immunother 2002, 25:359-372.
27. Tatsumi T, Kierstead LS, Ranieri E, et al.: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002, 196:619-628.
28. Sakaguchi S, Sakaguchi N, Asano M, et al.: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
29. Antony PA, Piccirillo CA, Akpinarli AS: et al.: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005, 174:2591-2601.
30. Chattopadhyay S, Chakraborty NG, Mukherji B: Regulatory T cells and tumor immunity. Cancer Immunol Immunother 2005 (Epub ahead of print).
31. Shimizu J, Yamazaki S, Takahashi T, et al.: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002, 3:135-42.
32. Turk MJ, Guevara-Patino JA, Rizzuto GA, et al.: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004, 200:771-782.
33. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909.
34. Dutcher J: Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Huntingt) 2002, 16:4-10.
35. Kirkwood JM, Manola J, Ibrahim J, et al.: A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004, 10:1670-1677.
36. Margolin KA: Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction. Cancer 2004, 101:435-438.
37. Rosenberg SA, Lotze MT, Yang JC, et al.: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993, 85:622-632.
38. Rosenberg SA, Yang JC, Topalian SL, et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 [see comments]. JAMA 1994, 271:907-913.
39. Chang AE, Aruga A, Cameron MJ, et al.: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997, 15:796-807.
40. Dudley ME, Wunderlich J, Nishimura MI, et al.: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001, 24:363-373.
41. Dudley ME, Wunderlich JR, Yang JC, et al.: A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002, 25:243-251.
42. Chang AE, Li Q, Jiang G, et al.: Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 2003, 21:884-890.
43. Hu HM, Winter H, Urba WJ, Fox BA: Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol 2000, 165:4246-4253.
44. Janssen EM, Droin NM, Lemmens EE, et al.: CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005, 434:88-93.
45. Janssen EM, Lemmens EE, Wolfe T, et al.: CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421:852-856.
46. Dudley ME, Wunderlich JR, Yang JC, et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005, 23:2346-2357.
47. Rosenberg SA, Aebersold P, Cornetta K, et al.: Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction [see comments]. N Engl J Med 1990, 323:570-578.
48. Dols A, Smith JW II, Meijer SL, et al.: Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther 2003, 14:1117-1123.
49. Weinberg AD: OX40: targeted immunotherapy: implications for tempering autoimmunity and enhancing vaccines. Trends Immunol 2002, 23:102-109.
50. Cheuk AT, Mufti GJ, Guinn BA: Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 2004, 11:215-226.
51. Croft M: Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev 2003, 14:265-273.
52. Kim YJ, Broxmeyer HE: Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8(+) T cells. J Hematother Stem Cell Res 2001, 10:441-449.
53. Conrad CT, Ernst NP, Dummer W, et al.: Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma. J Exp Clin Cancer Res 1999, 18:225-232.
54. Ichim CV: Revisiting immunosurveillance and immunostimulation: implications for cancer immunotherapy. J Transl Med 2005, 3:8.
55. Berthier-Vergnes O, Gaucherand M, Peguet-Navarro J, et al.: Human melanoma cells inhibit the earliest differentiation steps of human Langerhans cell precursors but failed to affect the functional maturation of epidermal Langerhans cells. Br J Cancer 2001, 85:1944-1951.
56. Kiertscher SM, Luo J, Dubinett SM, Roth MD: Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000, 164:1269-1276.
57. Wei WZ, Morris GP, Kong YC: Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 2004, 53:73-8.
58. Jones E, Dahm-Vicker M, Simon AK, et al.: Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002, 2:1.
59. Wolf AM, Wolf D, Steurer M, et al.: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003, 9:606-612.
60. Ormandy LA, Hillemann T, Wedemeyer H, et al.: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005, 65:2457-2464.
61. Korangy F, Ormandy LA, Bleck JS, Klempnauer J, et al.: Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 2004, 10:4332-4341.
62. Curiel TJ, Coukos G, Zou L, et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
63. Delong P, Carroll RG, Henry AC, et al.: Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 2005, 4 [Epub ahead of print].
64. Sasada T, Kimura M, Yoshida Y, et al.: CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003, 98:1089-1099.
65. Chakraborty NG, Chattopadhyay S, Mehrotra S, et al.: Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 2004, 65:794-802.
66. Hu HM, Poehlein CH, Urba WJ, Fox BA: Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 2002, 62:3914-3919.
67. Ma J, Urba WJ, Si L, et al.: Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol 2003, 33:2123-2132.
68. Ma J, Poehlein CH, Jensen SM, et al.: Manipulating the host response to autologous tumour vaccines. Dev Biol (Basel) 2004, 116:93-107.